Abby Jacobson

599 total citations
52 papers, 386 citations indexed

About

Abby Jacobson is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Abby Jacobson has authored 52 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Immunology, 27 papers in Dermatology and 10 papers in Physiology. Recurrent topics in Abby Jacobson's work include Psoriasis: Treatment and Pathogenesis (43 papers), Dermatology and Skin Diseases (21 papers) and Asthma and respiratory diseases (10 papers). Abby Jacobson is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (43 papers), Dermatology and Skin Diseases (21 papers) and Asthma and respiratory diseases (10 papers). Abby Jacobson collaborates with scholars based in United States, Canada and France. Abby Jacobson's co-authors include Mark Lebwohl, Alan Menter, Jennifer Soung, Robert J. Israel, Andrew Blauvelt, L. Puig, Jeffrey M. Sobell, H. Bachelez, Kim Papp and Edward Lain and has published in prestigious journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology and Lasers in Surgery and Medicine.

In The Last Decade

Abby Jacobson

43 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abby Jacobson United States 12 350 253 76 64 53 52 386
Eleonora Cinelli Italy 15 363 1.0× 328 1.3× 103 1.4× 60 0.9× 40 0.8× 36 540
M. Ruer‐Mulard France 7 376 1.1× 288 1.1× 55 0.7× 73 1.1× 68 1.3× 18 522
Q. Li United States 6 318 0.9× 221 0.9× 91 1.2× 65 1.0× 39 0.7× 20 367
S. D’Adamio Italy 14 348 1.0× 235 0.9× 97 1.3× 88 1.4× 51 1.0× 23 451
Arvin Ighani Canada 12 228 0.7× 150 0.6× 41 0.5× 59 0.9× 34 0.6× 19 290
Hany Elmaraghy United States 9 261 0.7× 315 1.2× 82 1.1× 62 1.0× 66 1.2× 30 419
Jingzhi Jiang United States 7 309 0.9× 279 1.1× 102 1.3× 41 0.6× 48 0.9× 10 399
Stephanie Mehlis United States 6 253 0.7× 151 0.6× 46 0.6× 53 0.8× 49 0.9× 14 310
Wendell C. Valdecantos United States 17 503 1.4× 386 1.5× 84 1.1× 75 1.2× 101 1.9× 32 618
Giovanna Malara Italy 12 231 0.7× 159 0.6× 65 0.9× 44 0.7× 60 1.1× 26 347

Countries citing papers authored by Abby Jacobson

Since Specialization
Citations

This map shows the geographic impact of Abby Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abby Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abby Jacobson more than expected).

Fields of papers citing papers by Abby Jacobson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abby Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abby Jacobson. The network helps show where Abby Jacobson may publish in the future.

Co-authorship network of co-authors of Abby Jacobson

This figure shows the co-authorship network connecting the top 25 collaborators of Abby Jacobson. A scholar is included among the top collaborators of Abby Jacobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abby Jacobson. Abby Jacobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friedman, Paul M., Jeffrey S. Dover, Anne Chapas, & Abby Jacobson. (2025). Current Trends and Future Directions of the Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System. Lasers in Surgery and Medicine. 57(7). 561–570.
2.
Polder, Kristel D., et al.. (2024). Nonablative Fractional Diode Laser Resurfacing (1440 nm and 1927 nm) for Photoaged Skin. Dermatologic Surgery. 51(1). 52–57. 2 indexed citations
3.
Lebwohl, Mark, John Koo, April W. Armstrong, et al.. (2024). Brodalumab: Six-Year US Pharmacovigilance Report. Dermatology and Therapy. 15(1). 213–222.
4.
Lebwohl, Mark, April W. Armstrong, Andrew Alexis, Edward Lain, & Abby Jacobson. (2024). Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses. Dermatology and Therapy. 14(10). 2709–2726. 2 indexed citations
5.
Lebwohl, Mark, John Koo, April W. Armstrong, et al.. (2024). Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and Therapy. 14(5). 1349–1357. 10 indexed citations
6.
Boh, Erin, et al.. (2023). Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma. Dermatology and Therapy. 13(3). 835–842. 6 indexed citations
7.
Kircik, Leon, Neal Bhatia, Edward Lain, & Abby Jacobson. (2023). Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene. Journal of Drugs in Dermatology. 22(3). 247–251. 1 indexed citations
8.
Draelos, Zoé Kececioglu, et al.. (2023). Fixed-combination halobetasol propionate and tazarotene topical lotion decreases TNF-α and IL-17A levels in psoriatic lesions. Journal of Dermatological Treatment. 34(1). 2245081–2245081.
9.
Menter, Alan, Tina Bhutani, Benjamin D. Ehst, Boni E. Elewski, & Abby Jacobson. (2022). Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatology and Therapy. 12(6). 1289–1302. 13 indexed citations
10.
Lebwohl, Mark, Alan Menter, Edward Lain, George Han, & Abby Jacobson. (2022). Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.. PubMed. 21(4). 354–370. 3 indexed citations
11.
Gottlieb, Alice B., et al.. (2020). Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. American Journal of Clinical Dermatology. 21(3). 421–430. 16 indexed citations
12.
Green, Lawrence, et al.. (2020). Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis. Journal of Drugs in Dermatology. 19(2). 138–143. 9 indexed citations
13.
Gold, Linda Stein, et al.. (2020). Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area. SKIN The Journal of Cutaneous Medicine. 4(6). s78–s78. 1 indexed citations
14.
Gold, Linda Stein, Boni E. Elewski, Zoe Draelos, Abby Jacobson, & Tina Lin. (2020). Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females. Journal of Drugs in Dermatology. 19(5). 504–514. 1 indexed citations
15.
Armstrong, April W., Bruce Strober, Benjamin D. Ehst, & Abby Jacobson. (2020). 15921 Absolute PASI response up to 52 weeks with brodalumab in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 83(6). AB164–AB164. 4 indexed citations
16.
Blauvelt, Andrew, et al.. (2020). Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. Journal of Drugs in Dermatology. 19(5). 487–492. 14 indexed citations
17.
Hsu, Sylvia, et al.. (2019). Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. British Journal of Dermatology. 182(4). 880–888. 22 indexed citations
18.
Lebwohl, Mark, Andrew Blauvelt, Alan Menter, et al.. (2019). Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American Journal of Clinical Dermatology. 20(6). 863–871. 30 indexed citations
19.
Puig, L., Mark Lebwohl, H. Bachelez, Jeffrey M. Sobell, & Abby Jacobson. (2019). Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial. Journal of the American Academy of Dermatology. 82(2). 352–359. 56 indexed citations
20.
Bagel, Jerry, Mark Lebwohl, Robert J. Israel, & Abby Jacobson. (2019). Immunogenicity and skin clearance recapture in clinical studies of brodalumab. Journal of the American Academy of Dermatology. 82(2). 344–351. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleonora Cinelli Breakdown of academic impact, for papers by M. Ruer‐Mulard Breakdown of academic impact, for papers by Q. Li Breakdown of academic impact, for papers by S. D’Adamio Breakdown of academic impact, for papers by Arvin Ighani Breakdown of academic impact, for papers by Hany Elmaraghy Breakdown of academic impact, for papers by Jingzhi Jiang Breakdown of academic impact, for papers by Stephanie Mehlis Breakdown of academic impact, for papers by Wendell C. Valdecantos Breakdown of academic impact, for papers by Giovanna Malara
Rankless by CCL
2026